Merck Opens Commercial Facility for CTDMO Services
Accelerating Biopharmaceutical Development and Manufacturing
Millipore CTDMO Services: A Comprehensive Suite of Offerings
Merck, a global leader in science and technology, has announced the grand opening of a commercial facility for its new Millipore CTDMO Services offering at the company's site in Martillac, France. This state-of-the-art facility provides comprehensive services to accelerate the development and commercialization of biopharmaceuticals.
The Millipore CTDMO Services encompass a wide range of capabilities, including:
- Analytical development
- Cell banking
- Cell line characterization
- Viral clearance
- Drug substance and drug product release testing
As the first CTDMO to offer integrated services for all critical stages of mRNA development, manufacturing, and testing, Merck is uniquely positioned to meet the evolving needs of the biopharmaceutical industry.
The growing demand for biologics and the increasing complexity of drug development have created a need for flexible and reliable partners. Merck's adaptable contract development and manufacturing solutions empower biotechs to bring their groundbreaking therapies to market efficiently.
With the inauguration of this commercial facility, Merck further strengthens its commitment to supporting biopharmaceutical innovation. The company's expertise in bioprocessing, testing, and regulatory compliance ensures the highest standards of quality and safety for complex biologics.
Komentar